Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential (HORIZON-HLTH-2027-01-DISEASE-05)
Development of novel small molecule antiviral therapeutics for pathogens with epidemic potential
- Closes
- 17 Feb 2027
- 95 days left
- Opened
- 29 Oct 2026
- Who can apply
- Research organisations, SMEs, Large companies, Consortia
- Open to applicants from
- European Union
What this call funds
Horizon Europe Cluster 1 Health call funding research to advance novel or existing small molecule antiviral candidates against one specified virus or virus group with epidemic potential, such as Lassa, Tick-borne encephalitis, Hantaan or Hendra virus. Antibody-based approaches are excluded. The single-stage deadline is 17 February 2027 at 17:00 CET, with opening on 29 October 2026; the page does not state the funding amount or consortium rules.
The call in detail
- Funder
- HaDEA
- Programme
- Horizon Europe Cluster 1: Health
- Type
- Grant
- Eligible applicants
- Research organisations, SMEs, Large companies, Consortia
- Eligible countries
- European Union
- Startup relevance
- Low
- Source
- HaDEA — calls for proposals
Key dates
- 29 Oct 2026
- Applications opened
- 17 Feb 2027
- Applications close
Earlier rounds and changes
| Recorded | What changed | Details |
|---|---|---|
| 13 Nov 2026 | First listed here | Already listed when the source was first read |
Similar open calls
Open calls like this one are listed for free accounts. Start with a free account to see them, save searches and get an e-mail when a new call matches.
Create free accountSummaries and extracted fields are generated automatically from the official page and may contain mistakes. Check the official page before applying.